Levetiracetam in refractory epilepsy: A prospective observational study

Seizure

Volumn 14, Issue 1, 2005, Pages 23-27

  Mohanraj, Rajiv ^a   Parker, Pamela G ^a   Stephen, Linda J ^a   Brodie, Martin J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Efficacy; Epilepsy; Levetiracetam; Open label study; Seizure; Side effects

Indexed keywords

ACETAZOLAMIDE; CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; AGGRESSION; ARTICLE; ATAXIA; BEHAVIOR DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; EPILEPSY; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MUSCLE WEAKNESS; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; SEDATION; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREMOR; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ELECTROENCEPHALOGRAPHY; EPILEPSIES, PARTIAL; EPILEPSY, GENERALIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PIRACETAM; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 12144249146     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2004.02.006     Document Type: Article

References (25)

1. Klitgaard H. Pitkanen A. Antiepileptogenesis, neuroprotection and disease modification in the treatment of epilepsy: Focus on levetiracetam Epileptic Disord. 5 Suppl 1 2003 S9-S16
2. Noyer M. Gillard M. Matagne A. The novel antiepileptic drug levetiracetam (UCB L059) appears to act via a specific binding site in CNS membranes Eur. J. Pharmacol. 286 1995 137-146
3. Birnstiel S. Wulfert E. Beck S.G. Levetiracetam (UCB LO59) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission Naunyn Schmiedebergs Arch. Pharmacol. 356 1997 611-618
4. Rigo J.M. Hans G. Nguyen L. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents Br. J. Pharmacol. 136 2002 659-672
5. Zona C. Niespodziany I. Marchetti C. et al. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents Seizure 10 2001 279-286
6. Loscher W. Honack D. Profile of ucb L059 a novel anticonvulsant drug in models of partial and generalized epilepsy in mice and rats Eur. J. Pharmacol. 232 1993 147-158
7. Gower A.J. Hirsch E. Boehrer A. et al. Effects of levetiracetam a novel antiepileptic drug on convulsant activity in two genetic rat models of epilepsy Epilepsy Res. 22 1995 207-213
8. Loscher W. Honack D. Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy J. Pharmacol. Exp. Ther. 284 1998 474-479
9. Patsalos P.N. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics Pharmacol. Ther. 85 2000 77-85
10. Cereghino J.J. Biton V. Abou-Khalil B. et al. Levetiracetam for partial seizures: Results of a double-blind randomized clinical trial Neurology 55 2000 236-242
11. Shorvon S.D. Lowenthal A. Janz D. et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures Epilepsia 41 2000 1179-1186
12. Betts T. Waegemans T. Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy Seizure 9 2000 80-87
13. Boon P. Chauvel P. Pohlmann-Eden B. et al. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy Epilepsy Res. 48 2002 77-89
14. Cramer J.A. Arrigo C. Van Hammee G. et al. Effect of levetiracetam on epilepsy-related quality of life Epilepsia 41 2000 868-874
15. Cohen J. Levetiracetam monotherapy for primary generalised epilepsy Seizure 12 2003 150-153
16. Lagae L, Buyse G, Deconinck A, Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Paediatr Neurol 2003 7 128
17. Abou-Khalil B. Hemdal P. Privitera M.D. An open-label study of levetiracetam at individualized doses between 1000 and 3000 mg/day in adult patients with refractory epilepsy Seizure 12 2003 141-149
18. Mohanraj R. Brodie M.J. Measuring the efficacy of antiepileptic drugs Seizure 12 2003 413-443
19. Annegers J.F. Hauser W.A. Elveback L.R. Remission of seizures in and relapse in patients with epilepsy Epilepsia 20 1979 729-737
20. Cockerell O.C. Johnson A.L. Sander J.W. et al. Remission of epilepsy: results from the National General Practice Study of Epilepsy Lancet 346 1995 140-144
21. Mattson J.H. Cramer J.A. Collins J.F. Prognosis for total control of complex partial and secondary generalised tonic-clonic seizures Neurology 47 1996 68-76
22. Kwan P. Brodie M.J. Early identification of refractory epilepsy N. Engl. J. Med. 342 2000 314-319
23. Brodie M.J. Do we need any more new antiepileptic drugs? Epilepsy Res. 45 2001 3-6
24. Brodie M.J. French J.A. Role of levetiracetam in the treatment of epilepsy Epileptic Disord. 5 Suppl 1 2003 S65-S72
25. White J.R. Walczak T.S. Leppik I.E. et al. Discontinuation of levetiracetam because of behavioural side effects Neurology 61 2003 1218-1221